Drugs in the Pipeline, News Rilzabrutinib Fails in Phase 3 Pemphigus Trial Publish Date September 9, 2021 Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
